An Israeli hospital on Monday said preliminary research indicates a fourth dose of the coronavirus vaccine provides only limited defence against the omicron variant that is raging around the world.
Sheba Hospital last month began administering a fourth vaccine to more than 270 medical workers — 154 who received a Pfizer-BioNTech vaccine and 120 others who received Moderna’s. All had previously been vaccinated three times with the Pfizer-BioNTech vaccine.
The clinical trial found that both groups showed increases in antibodies “slightly higher” than following the third vaccine last year. But it said the increased antibodies did not prevent the spread of omicron.
“Despite increased antibody levels, the fourth vaccine only offers a partial defence against the virus,” said Dr Gili Regev-Yochay, director of the hospital’s infection disease unit.
“The vaccines, which were more effective against previous variants, offer less protection versus omicron.”
ALSO READ: EFCC: Court grants Mompha N200m bail
The preliminary results raised questions about Israel’s decision to offer a second booster shot — and fourth overall — to its over-60 population. The government says over 500,000 people have received the second booster in recent weeks.
Dr. Nahman Ash, director of Israel’s Health Ministry, said the research did not mean the fourth vaccine effort was a mistake. “It returns the level of antibodies to what it was at the beginning of the third booster. That has great importance, especially among the older population,” he told Channel 13 TV.
But he said the research would be taken into account as authorities debate whether to expand the additional booster campaign to the broader population.
[Associated Press]
NewsWireNGR Latest News in Nigeria
Send Us A Press Statement/News Tips: [email protected]
Advertise With Us: [email protected]
